<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company said Friday.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 136.72

Destination
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 107.81

Destination
Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more... [...]

Match Score: 94.89

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 85.15

Destination
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more... [...]

Match Score: 73.96

qz
Hims & Hers will get to sell Ozempic. Like, real Ozempic. The stock soars 50%

Novo Nordisk and Hims had clashed on and off for months as the telehealth firm marketed compounded versions of Novo's blockbuster GLP-1 drug Wegovy [...]

Match Score: 67.03

Destination
Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read more... [...]

Match Score: 64.34

Destination
Ozempic is getting cheaper as Novo Nordisk rushes to undercut Eli Lilly

Nordisk starts offering cash buyers a two-month introductory price of $199 per month for Ozempic and Wegovy [...]

Match Score: 63.18

Destination
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]

Match Score: 62.96